| Vol. 13.39 – 28 October, 2021 |
| |
|
|
| Using mice models and human samples, scientists investigated the physiological requirement for endothelial cell BH4 in uteroplacental vascular adaptation and blood pressure regulation to pregnancy. [Hypertension] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers examined the association between placental paraben levels and cord blood metabolic biomarkers, considering modulating effects of maternal pre-pregnancy BMI and underlying epigenetic mechanisms, and investigated longitudinal effects of in utero paraben exposure on early childhood trajectories of BMI z-scores. [Environment International] |
|
|
|
| Scientists demonstrated that placenta-derived mesenchymal stem cells improved hepatic functions by regulating endoplasmic reticulum stress and calcium channels in a rat model of bile duct ligation. [Stem Cell Research & Therapy] |
|
|
|
| Investigators explored the possible mechanism of hepatocyte growth factor-transfectedhuman umbilical cord mesenchymal stem cells in inhibiting the proliferation and activation of hepatic stellate cells-T6. [Stem Cells and Development] |
|
|
|
| Scientists demonstrated that trophoblast-derived exosome proteins were one of the most critical elements in fetomaternal interaction, and their changes might act as a key signal in altering endometrial receptivity and provided a potential target for improving fertility. [Journal of Reproduction and Development] |
|
|
|
| MSCs were extracted from adipose, umbilical cord, and placental tissues. The surface marker expression, multilineage differentiation potential and cytokine secretion of these cells were compared. [Cellular Reprogramming] |
|
|
|
|
|
| Scientists systematically asses the diagnostic test accuracy of umbilical cord blood culture for early-onset sepsis. [Pediatric Research] |
|
|
|
|
| Cryo-Cell International, Inc. acquired exclusive commercial rights to a range of intellectual property assets and FDA regulatory data around several cord blood and cord tissue derived cell therapy products that had completed Phase I/Phase II clinical trials. [Cryo-Cell International, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| November 9 – 10, 2021 Montpellier, France |
|
|
|
|
|
| Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| Duke University – Durham, North Carolina, United States |
|
|
|
| Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| The University of Kansas – Kansas City, Kansas, United States |
|
|
|
| King Abdullah University of Science and Technology – Thuwal, Saudi Arabia |
|
|
|
|